Adicet Bio, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Adicet Bio, Inc. (ACET) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-03-19
- Adicet Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- Adicet Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- Adicet Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was -$14.00K.
- Adicet Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- Adicet Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Adicet Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.33M.
- Adicet Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Adicet Bio, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $22.37M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 10-K · filed 2024-03-19 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 | |||
| 2022-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$14.00K derived: sum of 2 quarters · filed 2024-03-19 | $2.33M derived: sum of 3 quarters · filed 2024-03-19 | $2.33M 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.34M derived: sum of 2 quarters · filed 2023-11-08 | $2.34M 10-Q · filed 2023-11-08 | $2.34M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.34M 10-Q · filed 2023-08-09 | $2.34M derived: sum of 3 quarters · filed 2023-08-09 | $2.34M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 10-K · filed 2023-03-15 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 | |||
| 2020-12-31 | $22.37M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |